MedPath

Zogenix, Inc.

Zogenix, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2006-01-01
Employees
327
Market Cap
-
Website
http://n/a

A Study to Investigate the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder

Phase 3
Recruiting
Conditions
CDKL5 Deficiency Disorder
Generalized Tonic Clonic Seizure
Epileptic Spasm
Refractory Seizures
Interventions
Drug: ZX008 (Fenfluramine Hydrochloride)
Drug: Matching ZX008 Placebo
First Posted Date
2021-10-01
Last Posted Date
2024-11-11
Lead Sponsor
Zogenix, Inc.
Target Recruit Count
100
Registration Number
NCT05064878
Locations
🇩🇪

Ep0216 901, Vogtareuth, Germany

🇮🇱

Ep0216 1909, Petah tikva, Israel

🇮🇹

Ep0216 1201, Florence, Italy

and more 60 locations

European Non-interventional Study on Refractory Epilepsy With Developmental Delay

Terminated
Conditions
Refractory Epilepsy
Development Delay
First Posted Date
2020-05-21
Last Posted Date
2023-12-01
Lead Sponsor
Zogenix, Inc.
Target Recruit Count
93
Registration Number
NCT04398667
Locations
🇩🇪

Gesellschaft für Epilepsieforschung e. V., Bielefeld, Germany

🇫🇷

Unité de neuropédiatrie, CHU Angers, Angers, France

🇫🇷

Department of Neurology - Foundation John Bost, La Force, France

and more 16 locations

A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome

Phase 3
Active, not recruiting
Conditions
Dravet Syndrome
Lennox Gastaut Syndrome
Epileptic Encephalopathy
Interventions
Drug: ZX008 (Fenfluramine Hydrochloride)
First Posted Date
2019-05-03
Last Posted Date
2024-07-25
Lead Sponsor
Zogenix, Inc.
Target Recruit Count
412
Registration Number
NCT03936777
Locations
🇺🇸

Ep0215 108, San Diego, California, United States

🇺🇸

Ep0215 101, San Francisco, California, United States

🇺🇸

Ep0215 106, Salt Lake City, Utah, United States

and more 68 locations

ZX008 Expanded Access Protocol

Conditions
Dravet Syndrome
First Posted Date
2018-12-19
Last Posted Date
2023-10-24
Lead Sponsor
Zogenix, Inc.
Registration Number
NCT03780127

Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia

Phase 1
Completed
Conditions
Schizoaffective Disorder
Schizophrenia
Interventions
Drug: ZX003 (Risperidone-SABER®)
Drug: Risperdal Consta
Drug: Oral Risperidone
First Posted Date
2015-04-08
Last Posted Date
2022-10-31
Lead Sponsor
Zogenix, Inc.
Target Recruit Count
60
Registration Number
NCT02411526
Locations
🇺🇸

Collaborative Neuroscience Network, Long Beach, California, United States

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Extended-Release (HC-ER) in Subjects With Renal Impairment

Phase 1
Completed
Conditions
Renal Impairment
Interventions
Drug: 20 mg HC-ER
First Posted Date
2014-09-19
Last Posted Date
2022-11-10
Lead Sponsor
Zogenix, Inc.
Target Recruit Count
37
Registration Number
NCT02244762

Pharmacokinetics and Metabolism of Hydrocodone Bitartrate Controlled-Release (HC-CR) in Subjects With Hepatic Impairment

Phase 1
Completed
Conditions
Hepatic Impairment
Interventions
Drug: 20 mg HC-ER
First Posted Date
2014-09-17
Last Posted Date
2022-11-10
Lead Sponsor
Zogenix, Inc.
Target Recruit Count
30
Registration Number
NCT02242734

A Safety, Tolerability and Pharmacokinetic Dose Escalation Study of HC-ER in Patients With Osteoarthritis Pain

Phase 2
Completed
Conditions
Osteoarthrosis
Interventions
Drug: 20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)
Drug: 10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)
First Posted Date
2014-08-21
Last Posted Date
2022-11-10
Lead Sponsor
Zogenix, Inc.
Target Recruit Count
37
Registration Number
NCT02222740

A Multicenter Active Comparator Study of HC-ER in Adults Following Bunionectomy Surgery

Phase 2
Completed
Conditions
Postoperative Pain
Interventions
Drug: Matching Placebo
Drug: 10 mg HC / 325 mg APAP
Drug: 10 mg HC-ER
Drug: 20 mg HC-ER
Drug: 30 mg HC-ER
Drug: 40 mg HC-ER
First Posted Date
2014-07-22
Last Posted Date
2022-11-10
Lead Sponsor
Zogenix, Inc.
Target Recruit Count
241
Registration Number
NCT02197156

A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: HC-ER + 20% Alcohol
Drug: HC-ER + 40% Alcohol
Drug: HC-ER + 0% Alcohol
First Posted Date
2014-04-30
Last Posted Date
2022-11-10
Lead Sponsor
Zogenix, Inc.
Target Recruit Count
30
Registration Number
NCT02126917
© Copyright 2025. All Rights Reserved by MedPath